Tag: intravenous immunoglobulin market outlook

Uncover key drivers, emerging technologies, and competitive movements shaping the intravenous immunoglobulin market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Intravenous Immunoglobulin Market And What Value Is Projected For 2029?

The intravenous immunoglobulin market size has experienced robust expansion over recent years. This market is projected to expand from $14.66 billion in 2024 to $15.57 billion by 2025, driven by a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion has been driven by several factors, including the treatment of primary immunodeficiency disorders, the management of various neurological conditions, an increasing geriatric population, improvements in plasma fractionation techniques, broader applications in neurology, the treatment of infectious diseases, and specific treatments for pediatric immunodeficiency.

The intravenous immunoglobulin market size is projected to experience substantial expansion over the upcoming years. It is anticipated to reach “$21.53 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.4%.” This growth during the forecast period can be attributed to factors such as an increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, a growing incidence of cancer, innovation in immunoglobulin products, and personalized medicine approaches. Major trends expected in the forecast period include advancements in primary immunodeficiency disorders (PIDD) treatment, rapid technological innovations, strategic collaborations and partnerships, improvements in manufacturing processes, expanding indications in neurology, increased use in hematology, and progress in immunotherapy.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Factors Are Boosting The Intravenous Immunoglobulin Market?

The growing geriatric population is anticipated to propel the intravenous immunoglobulin market. This demographic refers to individuals above 65 years of age. As people age, their immune systems often function less effectively, resulting in a deficiency of antibodies. Consequently, they require immunoglobulins to provide them with necessary antibodies. This increased need for intravenous immunoglobulins is expanding market demand. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. As a result, the increasing geriatric population will drive the growth of the intravenous immunoglobulin market forward.

What Are The Core Segmentation Criteria In The Intravenous Immunoglobulin Market?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Which Emerging Trends Are Reshaping The Intravenous Immunoglobulin Market Landscape?

Product innovation represents a significant trend gaining momentum in the intravenous immunoglobulin market. Major companies in this sector are concentrating on developing new offerings, such as liquid immune globulin formulations for treating immunodeficiency diseases, to strengthen their market presence. For instance, in December 2023, GC Pharma, a South Korea-based pharmaceutical company, introduced its US Food and Drug Administration (FDA) approved product, Alyglo. This sterile, ready-to-use liquid formulation contains 10% immunoglobulin G (IgG), supplying 100 mg/mL of protein, with at least 96% being human IgG derived from pooled human plasma. Its specific indication is for the management of primary humoral immunodeficiency (PI) in adults aged 17 years and older, covering conditions like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Players Are Shaping The Competitive Landscape Of The Intravenous ImmunoglobulinXX Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

What Regional Trends Are Shaping Growth In The Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Browse Through More Reports Similar to the Global Intravenous Immunoglobulin Market 2025, By The Business Research Company

Immunoglobulins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Immunosuppressant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report

Immunofluorescence Assay Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunofluorescence-assay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Intravenous Immunoglobulin Industry By The Forecast Year 2029?

The intravenous immunoglobulin market has seen substantial growth in recent years. This market is projected to expand from $14.66 billion in 2024 to $15.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.2%. The expansion observed historically is attributable to factors such as the treatment of primary immunodeficiency disorders, the management of neurological disorders, an increasing geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, the treatment of infectious diseases, and pediatric immunodeficiency treatment.

The intravenous immunoglobulin market is projected to experience significant expansion over the next few years. It is expected to reach $21.53 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period can be attributed to the rising occurrence of autoimmune disorders, continuous research in immunology, increasing healthcare spending, a surge in cancer incidence, innovations in immunoglobulin products, and personalized medicine approaches. Prominent trends for the forecast period include the treatment of primary immunodeficiency disorders (PIDD), rapid technological advancements, strategic collaborations and partnerships, improvements in manufacturing processes, new applications in neurology, use in hematology, and progress in immunotherapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Intravenous Immunoglobulin Industry?

The growth in the geriatric population is anticipated to propel the intravenous immunoglobulin market. The geriatric population refers to individuals above 65 years of age. As people advance in years, their immune system often functions less effectively, leading to a deficiency of antibodies. Therefore, they require immunoglobulins to provide them with the necessary antibodies. This situation boosts the demand for intravenous immunoglobulins, thus advancing the intravenous immunoglobulin market. For instance, in January 2024, the Population Reference Bureau, a Kenya-based Nonprofit organization, reported that the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. This age group’s proportion of the total population is also expected to climb from 17% to 23% over the same period. Consequently, the expanding geriatric population will stimulate the expansion of the intravenous immunoglobulin market.

How Is The Intravenous Immunoglobulin Market Segmented?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

How Are Trends Influencing The Intravenous Immunoglobulin Market?

Product innovation is a significant trend gaining momentum in the intravenous immunoglobulin market. Major companies are prioritizing the development of new products, such as liquid immune globulin formulations for treating immunodeficiency diseases, to maintain their competitive position. As an illustration, in December 2023, GC Pharma, a pharmaceutical company based in South Korea, launched Alyglo, which received approval from the US Food and Drug Administration (FDA). This product is a sterile, ready-to-use liquid formulation containing 10% immunoglobulin G (IgG), offering 100 mg/mL of protein, with at least 96% being human IgG derived from pooled human plasma. It is specifically prescribed for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older, covering conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Key Players Are Driving Competition In The Intravenous Immunoglobulin Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Geographies Are Emerging As Strong Markets For The Intravenous Immunoglobulin Industry?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Intravenous Immunoglobulin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Browse Through More Reports Similar to the Global Intravenous Immunoglobulin Market 2025, By The Business Research Company

Immunoglobulins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Immunosuppressant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report

Immunofluorescence Assay Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunofluorescence-assay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Intravenous Immunoglobulin Industry By 2029?

The market for intravenous immunoglobulin has seen substantial growth over recent years. The market value is expected to increase from $14.66 billion in 2024 to $15.57 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The previous growth can be credited to its use in treating primary immunodeficiency disorders, handling neurological conditions, increased elderly population, advancements in techniques for plasma fractionation, expansion in neurological indications, and its role in treating infectious diseases and pediatric immunodeficiency.

The market size for intravenous immunoglobulin is poised to witness robust expansion in the coming years, projected to reach $21.53 billion by 2029 with a CAGR of 8.4%. This prospective growth during the forecast period can be ascribed to a surge in autoimmune disorders, intensified immunology research, escalating healthcare costs, a rise in cancer rates, novel immunoglobulin products, and personalized medicine approaches. The forecast period also anticipates key trends such as treatment for primary immunodeficiency disorders (PIDD), swift technological evolution, strategic collaborations and alliances, enhancements in manufacturing methodologies, neurological applications, use in the field of hematology, and advancements in immunotherapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Growth-Enabling Forces Are Impacting The Intravenous Immunoglobulin Market?

The advancing age of the population is predicted to propel the intravenous immunoglobulin market forward. The term ‘geriatric population’ pertains to those who are 65 years of age or older. As age increases, the immune system does not function as effectively and there is a deficiency in antibodies. Consequently, they require immunoglobulins to supply them with the necessary antibodies. This raises the demand for intravenous immunoglobulins and propels the intravenous immunoglobulin market. For example, in January 2024, the Population Reference Bureau, a Nonprofit organization based in Kenya, projected that the American population aged 65 and older will swell from 58 million in 2022 to 82 million by 2050, marking a 47% increase. The proportion of this age group within the overall population is also anticipated to climb from 17% to 23% over the same stretch of time. Therefore, the escalating older population will fuel the progress of the intravenous immunoglobulin market.

Which Segmentation Factors Are Critical In The Intravenous Immunoglobulin Market Analysis?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

What Are The Dominant Trends Currently Seen In The Intravenous Immunoglobulin Market?

A significant trend growing in prominence within the intravenous immunoglobulin market is product innovation. Numerous prominent businesses are concentrating on creating novel products such as liquid immune globulin formulations for the treatment of immunodeficiency diseases, in a bid to maintain their market position. For instance, GC Pharma, a pharmaceutical firm based in South Korea, rolled out its FDA-approved product, Alyglo, in December 2023. This product is a sterile, ready-to-use liquid formulation with a composition of 10% immunoglobulin G (IgG), which equates to 100 mg/mL of protein, and at least 96% of this is human IgG procured from combined human plasma. Alyglo is primarily used for treating primary humoral immunodeficiency (PI) in adults who are 17 years and older. This includes aspects like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Players Are Shaping The Competitive Landscape Of The Intravenous Immunoglobulin Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Intravenous Immunoglobulin Market Heading Into 2029?

The market size for intravenous immunoglobulin has exhibited significant growth in the past few years. The forecast shows it will expand from $14.66 billion in 2024 to $15.57 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. This surge during the historic period can be attributed to its use in the treatment of primary immunodeficiency conditions, handling of neurological disorders, an increasing aging population, advancements in techniques for plasma fractionation, widened applications in neurology, and treatments for infectious diseases and pediatric immunodeficiency.

The market for intravenous immunoglobulin is forecasted to experience notable expansion in the coming years, with projections suggesting it will reach a value of $21.53 billion by 2029, with an 8.4% compound annual growth rate (CAGR). This expected increase over the forecast period is largely due to several factors, such as the increasing prevalence of autoimmune disorders, ongoing advancements in immunology research, a rise in healthcare spending, growing incidence of cancer, innovation in immunoglobulin products, and the rise of personalized medicine approaches. Key trends to look for during the forecast period include treatment developments for primary immunodeficiency disorders (PIDD), swift technological innovations, strategic alliances and partnerships, advancements in manufacturing procedures, neurological applications, uses in hematology, and developments in immunotherapy techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Which Factors Are Pushing The Intravenous Immunoglobulin Market Forward?

The rise in the elderly population is projected to propel the advancement of the intravenous immunoglobulin market. The term “elderly population” pertains to individuals who are 65 years old and above. With advancing age, the immune system tends to malfunction and there is a scarcity of antibodies. Hence, these individuals require immunoglobulins to supply them with necessary antibodies. This escalated need fuels the demand for intravenous immunoglobulis and propels the intravenous immunoglobulin market. For example, projections from the Population Reference Bureau, a nonprofit organization based in Kenya, stated that by January 2024, the population of Americans aged 65 and older is set to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. The proportion of this age bracket in comparison to the total population is also expected to grow from 17% to 23% within the same timeframe. Consequently, an uptick in the elderly population is anticipated to spur the expansion of the intravenous immunoglobulin market.

Which Segment Held The Largest Share In The Intravenous Immunoglobulin Market In 2025?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

How Are Key Trends Driving Expansion In The Intravenous Immunoglobulin Industry?

Emerging as a major trend in the intravenous immunoglobulin market, product innovation is increasingly being prioritized by leading companies. These organizations are striving to introduce innovative new products such as liquid immune globulin treatments specifically for immunodeficiency conditions in order to solidify their market standing. For instance, GC Pharma, a pharmaceutical organization based in South Korea, launched an FDA-approved product named Alyglo in December 2023. This new solution is a sterile, pre-prepared liquid formulation comprising 10% immunoglobulin G (IgG), which delivers 100 mg/mL of protein, including a minimum of 96% human IgG acquired from collective human plasma. It is outlined specifically for treating primary humoral immunodeficiency (PI) in adults aged 17 years and above, targeting diseases like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Organizations Are Driving Progress In The Intravenous Immunoglobulin Industry?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Intravenous Immunoglobulin Industry?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Intravenous Immunoglobulin Market from 2024 to 2025?

Recent years have seen significant expansion in the intravenous immunoglobulin market size. The market, which is set to progress from $14.66 billion in 2024 to $15.72 billion in 2025, has a compound annual growth rate (CAGR) of 7.2%. This robust growth in the previous period has been driven by several factors. These include treating primary immune deficiency disorders, managing neurological disorders, a growing older population, advances in plasma fractionation techniques, broadened indications in neurology, and treating infectious diseases along with pediatric immune deficiency.

What Is the Projected Market Size of the Intravenous Immunoglobulin Market?

In the coming years, the intravenous immunoglobulin market is predicted to experience significant expansion, reaching a market size of $22.01 billion by 2029 through an annual growth rate of 8.8%. The forecasted period’s growth could be due to various factors such as a surge in autoimmune disorders, ongoing immunology research, increased spending in healthcare, rising cancer cases, innovative immunoglobulin products, and personalized medicine approaches. The period may also witness primary trends such as the treatment of primary immunodeficiency disorders (PIDD), fast-paced technological innovations, strategic collaborations and partnerships, developments in manufacturing processes, neurology indications, usage in hematology, and progress in immunotherapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Who are the Major Competitors in the Intravenous Immunoglobulin Market Outlook?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

What Is Fueling Growth in the Intravenous Immunoglobulin Market?

The growth of the intravenous immunoglobulin market is projected to be fueled by the rise in the elderly population. Individuals above 65 years old are typically considered part of the geriatric population. As they age, their immune systems become less effective, resulting in an insufficient amount of antibodies. Hence, there is a need for immunoglobulins to supplement these antibodies. This causes a surge in the demand for intravenous immunoglobulins, thus propelling the intravenous immunoglobulin market. For example, the Population Reference Bureau, a nonprofit organization based in Kenya, revealed in January 2024 that the American population aged 65 and older is forecasted to substantially increase from 58 million in 2022 to 82 million by 2050, signifying a 47% increment. Concurrently, it is expected that this demographic will make up 23% of the total population, a rise from the current 17%. Thus, the escalating elderly population will undoubtedly spur the expansion of the intravenous immunoglobulin market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Which Intravenous Immunoglobulin Market Segments Are Growing the Fastest?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Which Industry Trends Are Shaping the Future of the Intravenous Immunoglobulin Market?

A notable developing trend in the intravenous immunoglobulin market is product innovation. To maintain their market presence and edge, major firms in this sector are emphasizing the concept of product innovation, introducing new items such as liquid immune globulin formulations for treating immunodeficiency diseases. An example of this is Alyglo, an innovative product launched by GC Pharma, a pharmaceutical firm based in South Korea, in December 2023. Authorized by the US Food and Drug Administration, Alyglo is a sterile, ready-to-use liquid containing 10% Immunoglobulin G (IgG), offering 100 mg/mL of protein, out of which a minimum of 96% is human IgG sourced from pooled human plasma. It is designated specifically for individuals aged 17 years and above suffering from primary humoral immunodeficiency (PI). The diseases that fall under this category include congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Countries Are Leading the Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

This Report Delivers Insight On:

1. How big is the intravenous immunoglobulin market, and how is it changing globally?

2. Who are the major companies in the intravenous immunoglobulin market, and how are they performing?

3. What are the key opportunities and risks in the intravenous immunoglobulin market right now?

4. Which products or customer segments are growing the most in the intravenous immunoglobulin market?

5. What factors are helping or slowing down the growth of the intravenous immunoglobulin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Intravenous Immunoglobulin Market from 2024 to 2025?

Recent years have seen significant expansion in the intravenous immunoglobulin market size. The market, which is set to progress from $14.66 billion in 2024 to $15.72 billion in 2025, has a compound annual growth rate (CAGR) of 7.2%. This robust growth in the previous period has been driven by several factors. These include treating primary immune deficiency disorders, managing neurological disorders, a growing older population, advances in plasma fractionation techniques, broadened indications in neurology, and treating infectious diseases along with pediatric immune deficiency.

What Is the Projected Market Size of the Intravenous Immunoglobulin Market?

In the coming years, the intravenous immunoglobulin market is predicted to experience significant expansion, reaching a market size of $22.01 billion by 2029 through an annual growth rate of 8.8%. The forecasted period’s growth could be due to various factors such as a surge in autoimmune disorders, ongoing immunology research, increased spending in healthcare, rising cancer cases, innovative immunoglobulin products, and personalized medicine approaches. The period may also witness primary trends such as the treatment of primary immunodeficiency disorders (PIDD), fast-paced technological innovations, strategic collaborations and partnerships, developments in manufacturing processes, neurology indications, usage in hematology, and progress in immunotherapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Who are the Major Competitors in the Intravenous Immunoglobulin Market Outlook?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

What Is Fueling Growth in the Intravenous Immunoglobulin Market?

The growth of the intravenous immunoglobulin market is projected to be fueled by the rise in the elderly population. Individuals above 65 years old are typically considered part of the geriatric population. As they age, their immune systems become less effective, resulting in an insufficient amount of antibodies. Hence, there is a need for immunoglobulins to supplement these antibodies. This causes a surge in the demand for intravenous immunoglobulins, thus propelling the intravenous immunoglobulin market. For example, the Population Reference Bureau, a nonprofit organization based in Kenya, revealed in January 2024 that the American population aged 65 and older is forecasted to substantially increase from 58 million in 2022 to 82 million by 2050, signifying a 47% increment. Concurrently, it is expected that this demographic will make up 23% of the total population, a rise from the current 17%. Thus, the escalating elderly population will undoubtedly spur the expansion of the intravenous immunoglobulin market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Which Intravenous Immunoglobulin Market Segments Are Growing the Fastest?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Which Industry Trends Are Shaping the Future of the Intravenous Immunoglobulin Market?

A notable developing trend in the intravenous immunoglobulin market is product innovation. To maintain their market presence and edge, major firms in this sector are emphasizing the concept of product innovation, introducing new items such as liquid immune globulin formulations for treating immunodeficiency diseases. An example of this is Alyglo, an innovative product launched by GC Pharma, a pharmaceutical firm based in South Korea, in December 2023. Authorized by the US Food and Drug Administration, Alyglo is a sterile, ready-to-use liquid containing 10% Immunoglobulin G (IgG), offering 100 mg/mL of protein, out of which a minimum of 96% is human IgG sourced from pooled human plasma. It is designated specifically for individuals aged 17 years and above suffering from primary humoral immunodeficiency (PI). The diseases that fall under this category include congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Countries Are Leading the Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

This Report Delivers Insight On:

1. How big is the intravenous immunoglobulin market, and how is it changing globally?

2. Who are the major companies in the intravenous immunoglobulin market, and how are they performing?

3. What are the key opportunities and risks in the intravenous immunoglobulin market right now?

4. Which products or customer segments are growing the most in the intravenous immunoglobulin market?

5. What factors are helping or slowing down the growth of the intravenous immunoglobulin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Intravenous Immunoglobulin Market from 2024 to 2025?

Recent years have seen significant expansion in the intravenous immunoglobulin market size. The market, which is set to progress from $14.66 billion in 2024 to $15.72 billion in 2025, has a compound annual growth rate (CAGR) of 7.2%. This robust growth in the previous period has been driven by several factors. These include treating primary immune deficiency disorders, managing neurological disorders, a growing older population, advances in plasma fractionation techniques, broadened indications in neurology, and treating infectious diseases along with pediatric immune deficiency.

What Is the Projected Market Size of the Intravenous Immunoglobulin Market?

In the coming years, the intravenous immunoglobulin market is predicted to experience significant expansion, reaching a market size of $22.01 billion by 2029 through an annual growth rate of 8.8%. The forecasted period’s growth could be due to various factors such as a surge in autoimmune disorders, ongoing immunology research, increased spending in healthcare, rising cancer cases, innovative immunoglobulin products, and personalized medicine approaches. The period may also witness primary trends such as the treatment of primary immunodeficiency disorders (PIDD), fast-paced technological innovations, strategic collaborations and partnerships, developments in manufacturing processes, neurology indications, usage in hematology, and progress in immunotherapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Who are the Major Competitors in the Intravenous Immunoglobulin Market Outlook?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

What Is Fueling Growth in the Intravenous Immunoglobulin Market?

The growth of the intravenous immunoglobulin market is projected to be fueled by the rise in the elderly population. Individuals above 65 years old are typically considered part of the geriatric population. As they age, their immune systems become less effective, resulting in an insufficient amount of antibodies. Hence, there is a need for immunoglobulins to supplement these antibodies. This causes a surge in the demand for intravenous immunoglobulins, thus propelling the intravenous immunoglobulin market. For example, the Population Reference Bureau, a nonprofit organization based in Kenya, revealed in January 2024 that the American population aged 65 and older is forecasted to substantially increase from 58 million in 2022 to 82 million by 2050, signifying a 47% increment. Concurrently, it is expected that this demographic will make up 23% of the total population, a rise from the current 17%. Thus, the escalating elderly population will undoubtedly spur the expansion of the intravenous immunoglobulin market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Which Intravenous Immunoglobulin Market Segments Are Growing the Fastest?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Which Industry Trends Are Shaping the Future of the Intravenous Immunoglobulin Market?

A notable developing trend in the intravenous immunoglobulin market is product innovation. To maintain their market presence and edge, major firms in this sector are emphasizing the concept of product innovation, introducing new items such as liquid immune globulin formulations for treating immunodeficiency diseases. An example of this is Alyglo, an innovative product launched by GC Pharma, a pharmaceutical firm based in South Korea, in December 2023. Authorized by the US Food and Drug Administration, Alyglo is a sterile, ready-to-use liquid containing 10% Immunoglobulin G (IgG), offering 100 mg/mL of protein, out of which a minimum of 96% is human IgG sourced from pooled human plasma. It is designated specifically for individuals aged 17 years and above suffering from primary humoral immunodeficiency (PI). The diseases that fall under this category include congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Countries Are Leading the Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

This Report Delivers Insight On:

1. How big is the intravenous immunoglobulin market, and how is it changing globally?

2. Who are the major companies in the intravenous immunoglobulin market, and how are they performing?

3. What are the key opportunities and risks in the intravenous immunoglobulin market right now?

4. Which products or customer segments are growing the most in the intravenous immunoglobulin market?

5. What factors are helping or slowing down the growth of the intravenous immunoglobulin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the intravenous immunoglobulin industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Intravenous Immunoglobulin Market Through 2034?

The market size for intravenous immunoglobulin has seen substantial growth in the recent past. The market is expected to expand from $14.66 billion in 2024 to $15.72 billion in 2025, marking a compound annual growth rate (CAGR) of 7.2%. This robust growth in the historic timeframe can be credited to factors such as the treatment of primary immunodeficiency disorders, management of neurological diseases, a surge in the elderly population, progress in plasma fractionation methods, broadened neurological indications, handling of infectious diseases, and the treatment of pediatric immunodeficiency.

The market for intravenous immunoglobulin is projected to experience substantial growth in the upcoming years, reaching $22.01 billion by 2029 with an annual compound growth rate (CAGR) of 8.8%. This expected growth can be linked to several factors such as a rising occurrence of autoimmune disorders, active immunology research, increasing healthcare spending, growing instances of cancer, innovative immunoglobulin products, and personalized medicine tactics. In the forecast period, we can anticipate trends such as treatments for primary immunodeficiency disorders (PIDD), swift progress in technology, strategic partnerships and collaborations, advancements in production methods, applications in neurology and hematology, and progress in immunotherapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Which Primay Drivers Are Accelerating Growth in the Intravenous Immunoglobulin Market?

The escalating number of older people will prompt expansion within the intravenous immunoglobulin market. Often referring to individuals who are over the age of 65, the geriatric population often face weakened immune responses and limited antibodies as a natural part of aging. This makes them more dependent on immunoglobulins to supply their bodies with essential antibodies, thereby boosting the demand for intravenous immunoglobulins and propelling the market. To illustrate, data from the Population Reference Bureau, a non-profit organization based in Kenya, anticipates an increase of 47% in the American population aged 65 and older, growing from 58 million in 2022 to 82 million by 2050. Furthermore, this age segment’s percentage within the total population is predicted to ascend from 17% to 23% in the same timeframe. Thus, the augmenting geriatric population indeed plays a significant role in advancing the intravenous immunoglobulin market.

Which Primary Segments of the Intravenous Immunoglobulin Market Are Driving Growth and Industry Transformations?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Which Regions Are Key Players in the Growth of the Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Intravenous Immunoglobulin Industry Dynamics?

The intravenous immunoglobulin market is witnessing an escalating trend in product innovation. Market-leading corporations are particularly focused on introducing novel items such as liquid immune globulin formulations, used for immunodeficiency diseases treatment, to retain their market stature. For example, GC Pharma, a pharmaceutical company based in South Korea, launched Alyglo, a product approved by the US Food and Drug Administration (FDA), in December 2023. This ready-to-use sterile liquid formulation includes 10% immunoglobulin G (IgG), with each milliliter containing 100 mg of protein of which at least 96% originates from human IgG obtained from collected human plasma. It is specially aimed for the treatment of primary humoral immunodeficiency (PI) in adults 17 years or older. This covers diseases like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

View the full report here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

What Parameters Are Used to Define the Intravenous Immunoglobulin Market?

Intravenous immunoglobulin refers to a therapy used for the treatment of immunodeficient people. It is administered in the form of intravenous infusion. Infusion liquid is made from immunoglobulins collected from healthy individuals and purified to eliminate any blood-borne infection or impurity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theIntravenous Immunoglobulin Market?

The upswing in the elderly population is predicted to propel the progress of the intravenous immunoglobulin market. The elderly demographic constitutes individuals who are 65 years old or over. Due to the reduction in immunity and the scarcity of antibodies in aging individuals, they require immunoglobulins to provide necessary antibodies. This propels the demand for intravenous immunoglobulins and thus stimulates the advance of the intravenous immunoglobulin market. For example, the Population Reference Bureau, headquartered in Kenya, projected in January 2024 that the American population aged 65 and above will increase by 47%, leaping from 58 million in 2022 to 82 million by 2050. The proportion of this age group within the total population is also forecasted to rise from 17% to 23% in the same time frame. Consequently, the surging number of elderly individuals will fuel the expansion of the intravenous immunoglobulin market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

#What Growth Opportunities Will Drive the Intravenous Immunoglobulin Market’s CAGR Through 2034?

The market size for intravenous immunoglobulin has experienced significant growth in recent years. It is predicted to increase from a value of $14.66 billion in 2024 to $15.72 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this historic growth include the treatment of primary immunodeficiency disorders, management of neurological conditions, an increase in the population of elderly individuals, advancements made in plasma fractionation techniques, and expanded indications in neurology, infectious disease treatment, and treatment of pediatric immunodeficiency.

The market size of intravenous immunoglobulin is predicted to undergo considerable expansion in the coming years, reaching $22.01 billion by 2029 with a compound annual growth rate (CAGR) of 8.8%. The projected increase during the forecast period can be credited to a heightened occurrence of autoimmune disorders, ongoing studies within the field of immunology, higher healthcare expenditures, increased instances of cancer, innovative developments in immunoglobulin products, and the application of personalized medicine methodologies. Leading trends during this forecast period are anticipated to be the treatment of primary immunodeficiency disorders (PIDD), fast-paced technological breakthroughs, strategic alliances and partnerships, improvements in manufacturing methods, neurology indications, uses in hematology, and the progress in immunotherapy.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

What Are the Latest Innovations Influencing theIntravenous Immunoglobulin Market?

A significant trend taking hold in the intravenous immunoglobulin marketplace is centred around product innovation. Leading companies are seeking to introduce new and innovative products such as fluid immune globulin formulae, which are aimed at addressing immunodeficiency illnesses, thereby maintaining their market stance. An example of this was seen in December 2023 when GC Pharma, a pharmaceutical firm from South Korea, released Alyglo which received the green light from the US Food and Drug Administration (FDA). Alyglo is a sterile, ready-for-use liquid solution that contains 10% immunoglobulin G (IgG), equating to 100 mg/mL of protein. At least 96% of this is human IgG that originates from pooled human plasma. It has been specially designed for the treatment of primary humoral immunodeficiency (PI) in adults who are 17 years or older, and this encompasses diseases like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Who Are the Major Industry Players Accelerating Growth in theIntravenous Immunoglobulin Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Primary Segments of the Intravenous Immunoglobulin Market Are Driving Growth and Industry Transformations?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smpGlobal Intravenous Immunoglobulin Market, Global Intravenous Immunoglobulin Market Report, Global Intravenous Immunoglobulin Market Trends, Global Intravenous Immunoglobulin Market Size

Browse Through More Reports Similar to the Gobal Intravenous Immunoglobulin Maret 2025, By The Business Research Company:

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Immunofluorescence Assay Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunofluorescence-assay-global-market-report

Immunoglobulins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: